Belite Bio (BLTE) Debt to Equity (2021)
Belite Bio (BLTE) recorded quarterly Debt to Equity of -$0.0 in Q4 2021.
Belite Bio (BLTE) Debt to Equity (2021) Analysis & Trends
Belite Bio's Debt to Equity history runs 1 years deep, the most recent figure standing at -$0.0 for Q4 2021.
- In Q4 2021, Debt to Equity changed N/A year-over-year to -$0.0; the TTM figure through Dec 2021 stood at -$0.0 (changed N/A YoY), while the FY2021 annual figure was -$0.0, changed N/A from the prior year.
- Debt to Equity was -$0.0 for Q4 2021 at Belite Bio.
- In the past five years, Debt to Equity ranged from a high of -$0.0 in Q4 2021 to a low of -$0.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.00 |